C677T (thermolabile alanine/valine) polymorphism in methylenetetrahydrofolate reductase (MTHFR): Its frequency and impact on plasma homocysteine concentration in different European populations

Atherosclerosis

Volumn 136, Issue 2, 1998, Pages 347-354

  Gudnason, Vilmundur ^a   Stansbie, David ^b   Scott, Jeff ^b   Bowron, Ann ^b   Nicaud, Viviane ^c   Humphries, Steve ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b BRISTOL ROYAL INFIRMARY   (United Kingdom)

^c INSERM   (France)

Author keywords

EARS; Genetic polymorphism; Homocysteine; Methylenetetrahydrofolate reductase

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); HOMOCYSTEINE;

ADULT; ALLELE; AMINO ACID BLOOD LEVEL; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; EUROPE; GENETIC POLYMORPHISM; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ALANINE; ALLELES; EUROPE; GENE FREQUENCY; GENETICS, POPULATION; GENOTYPE; HETEROZYGOTE; HOMOCYSTEINE; HOMOZYGOTE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MYOCARDIAL INFARCTION; OXIDOREDUCTASES ACTING ON CH-NH GROUP DONORS; POINT MUTATION; POLYMORPHISM, GENETIC; VALINE;

EID: 0032005443     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(97)00237-2     Document Type: Article

References (48)

1. Wilcken D.E., Wilcken B. The pathogenesis of coronary artery disease. A possible role for methionine metabolism. J Clin Invest. 57:1976;1079-1082.
2. Wilcken D.E., Reddy S.G., Gupta V.J. Homocysteinemia, ischemic heart disease, and the carrier state for homocystinuria. Metabolism. 32:1983;363-370.
3. Brattstrom L.E., Hardebo J.E., Hultberg B.L. Moderate homocysteinemia: a possible risk factor for arteriosclerotic cerebrovascular disease. Stroke. 15:1984;1012-1016.
4. Boers G.H., Smals A.G., Trijbels F.J., Fowler B., Bakkeren J.A., Schoonderwaldt H.C., Kleijer W.J., Kloppenborg P.W. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med. 313:1985;709-715.
5. Murphy Chutorian D.R., Wexman M.P., Grieco A.J., Heininger J.A., Glassman E., Gaull G.E., Ng S.K., Feit F., Wexman K., Fox A.C. Methionine intolerance: a possible risk factor for coronary artery disease. J Am Coll Cardiol. 6:1985;725-730.
6. Kang S.S., Wong P.W., Cook H.Y., Norusis M., Messer J.V. Protein-bound homocyst(e)ine. A possible risk factor for coronary artery disease. J Clin Invest. 77:1986;1482-1486.
7. Israelsson B., Brattstrom L.E., Hultberg B.L. Homocysteine and myocardial infarction. Atherosclerosis. 71:1988;227-233.
8. Malinow M.R., Kang S.S., Taylor L.M., Wong P.W., Coull B., Inahara T., Mukerjee D., Sexton G., Upson B. Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease. Circulation. 79:1989;1180-1188.
9. Malinow M.R., Sexton G., Averbuch M., Grossman M., Wilson D., Upson B. Homocyst(e)inemia in daily practice: levels in coronary artery disease. Coron Artery Dis. 1:1990;215-220.
10. Genest J.J. Jr., McNamara J.R., Salem D.N., Wilson P.W., Schaefer E.J., Malinow M.R. Plasma homocyst(e)ine levels in men with premature coronary artery disease. J Am Coll Cardiol. 16:1990;1114-1119.
11. Genest J.J. Jr., McNamara J.R., Upson B., Salem D.N., Ordovas J.M., Schaefer E.J., Malinow M.R. Prevalence of familial hyperhomocyst(e)inemia in men with premature coronary artery disease. Arterioscler Thromb. 11:1991;1129-1136.
12. Clarke R., Daly L., Robinson K., Naughten E., Cahalane S., Fowler B., Graham I. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 324:1991;1149-1155.
13. Stampfer M.J., Malinow M.R., Willett W.C., Newcomer L.M., Upson B., Ullmann D., Tishler P.V., Hennekens C.H. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. J Am Med Assoc. 268:1992;877-881.
14. Malinow M.R., Nieto F.J., Szklo M., Chambless L.E., Bond G. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. The Atherosclerosis Risk in Communities Study. Circulation. 87:1993;1107-1113.
15. Selhub J., Jacques P.F., Bostom A.G., D'Agostino R.B., Wilson P.W., Belanger A.J., O'Leary D.H., Wolf P.A., Schaefer E.J., Rosenberg I.H. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med. 332:1995;286-291.
16. Malinow M.R., Ducimetiere P., Luc G., Evans A.E., Arveiler D., Cambien F., Upson B.M. Plasma homocyst(e)ine levels and graded risk for myocardial infarction: findings in two populations at contrasting riak for coronary heart disease. Atherosclerosis. 126:1996;27-34.
17. Arnesen E., Refsum H., Bonaa K.H., Ueland P.M., Forde O.H., Nordrehaug J.E. Serum total homocysteine and coronary heart disease. Int J Epidemiol. 24:1995;704-709.
18. Alfthan G., Pekkanen J., Jauhiainen M., Pitkaniemi J., Karvonen M., Tuomilehto J., Salonen J.T., Ehnholm C. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis. 106:1994;9-19.
19. Kang S.S., Wong P.W. Genetic and nongenetic factors for moderate hyperhomocyst(e)inemia. Atherosclerosis. 119:1996;135-138.
20. Mudd SH, Levy HL, Skovby F. Disorders of transsulfuration. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The Metabolic Basis of Inherited Disease. New York: McGraw-Hill, 1989: 693-734.
21. Rosenblatt DS, Inherited disorders of folate transport and metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The Metabolic and Molecular Basis of Inherited Disease. New York: McGraw-Hill, 1995: 3111-3128.
22. Kang S.S., Wong P.W., Bock H.G., Horwitz A., Grix A. Intermediate hyperhomocysteinemia resulting from compound heterozygosity of methylenetetrahydrofolate reductase mutations. Am J Hum Genet. 48:1991;546-551.
23. Engbersen A.M., Franken D.G., Boers G.H., Stevens E.M., Trijbels F.J., Blom H.J. Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am J Hum Genet. 56:1995;142-150.
24. Frosst P., Blom H.J., Milos R., Goyette P., Sheppard C.A., Matthews R.G., Boers G.J., den Heijer M., Kluijtmans L.A., van den Heuvel L.P.et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 10:1995;111-113.
25. Jacques P.F., Bostom A.G., Williams R.R., Ellison R.C., Eckfeldt J.H., Rosenberg I.H., Selhub J., Rozen R. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation. 93:1996;7-9.
26. van der Put N.M., Steegers Theunissen R.P., Frosst P., Trijbels F.J., Eskes T.K., van den Heuvel L.P., Mariman E.C., den Heyer M., Rozen R., Blom H.J. Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet. 346:1995;1070-1071.
27. Kluijtmans L.A., van den Heuvel L.P., Boers G.H., Frosst P., Stevens E.M., van Oost B.A., den Heijer M., Trijbels F.J., Rozen R., Blom H.J. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet. 58:1996;35-41.
28. Harmon D.L., Woodside J.V., Yarnell J.W.G., McMaster D., Young I.S., McCrum E.E., Gey K.F., Whitehead A.S., Evans A.E. The common 'thermolabile' variant of methylenetetrahydrofolate reductase is a major determinant of mild hyperhomocysteinaemia. Q J Med. 89:1996;571-577.
29. Ma J., Stampfer M.J., Hennekens C.H., Frosst P., Selhub J., Horsford J., Manilow M.R., Willett W.C., Rozen R. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine and risk of myocardial infarction in US physicians. Circulation. 94:1996;2410-2416.
30. Schmitz C., Lindpainter K., Verhoef P., Gaziano J.M., Buring J. Genetic polymorphism of methlenetetrahydrofolate reductase and myocardial infarction. A case-control study. Circulation. 94:1996;1812-1814.
31. Guttormsen A.B., Ueland P.M., Nesthus I., Nygård O., Schneede J., Vollset S.E., Refsum H. Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (≥40 μmol/l). The Hordaland homocysteine study. J Clin Invest. 98:1996;2174-2183.
32. Kang S.S., Passen E.L., Ruggie N., Wong P.W., Sora H. Thermolabile defect of methylenetetrahydrofolate reductase in coronary artery disease. Circulation. 88:1993;1463-1469.
33. Gallagher P.M., Meleady R., Sheilds D.C., Tan K.S., McMaster D., Rozen R., Evans A., Graham I.M., Whitehead A.S. Homocysteine and risk of premature coronary heart disease. Evidence for a common gene mutation. Circulation. 94:1996;2154-2158.
34. Deloughery T.G., Evans A., Sadeghi A., McWilliams J., Henner W.D., Taylor L.M., Press R.D. Common mutation in methylenetetrahydrofolate reductase. Correlation with homocysteine metabolism and late-onset vascular disease. Circulation. 94:1996;3074-3078.
35. Wilcken D.E., Wang X.L., Sim A.S., McCredie R.M. Distribution in healthy and coronary populations of the methylenetetrahydrofolate reductase (MTHFR) C677T mutation. Arterioscler Thromb Vasc Biol. 16:1996;878-882.
36. van Bockxmeer F.M., Marmotte C.D.S., Vasikaran S.D., Taylor R.R. Methylenetetrahydrofolate reductase gene and coronary artery disease. Circulation. 95:1997;21-23.
37. Brugada R., Marian A.J. A common mutation in methylenetetrahydrofolate reducase gene is not a major risk of coronary artery disease or myocardial infarction. Atherosclerosis. 128:1997;107-112.
38. The European Atherosclerosis Research Study (EARS). Design and Objectives. Int J Epidemiol 1994;23:465-471.
39. Fiskerstrand T., Refsum H., Kvalheim G., Ueland P.M. Homocysteine and other thiols in plasma and urine: automated determination and sample stability. Clin Chem. 39:1993;263-271.
40. Miller S.A., Dykes D.D., Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16:1988;1215.
41. Bolla M.K., Haddad L., Humphries S.E., Winder A.F., Day I.N. High-throughput method for determination of apolipoprotein E genotypes with use of restriction digestion analysis by microplate array diagonal gel electrophoresis. Clin Chem. 41:1995;1599-1604.
42. Day I.N., Humphries S.E. Electrophoresis for genotyping: microtiter array diagonal gel electrophoresis on horizontal polyacrylamide gels, hydrolink, or agarose. Anal Biochem. 222:1994;389-395.
43. Motulsky A.G. Nutritional ecogenetics: homocysteine-related arteriosclerotic vascular disease, neural tube defects, and folic acid. Am J Hum Genet. 58:1996;17-20.
44. Tiret L., Nicaud V., Ehnholm C., Havekes L., Menzel H.J., Ducimetiere P., Cambien F. Inference of the strength of genotype-disease association from studies comparing offspring with and without parental history of disease. Ann Hum Genet. 57:1993;141-149.
45. Nygård O., Refsum H., Ueland P., Stensvold I., Norderhaug J., Kvale G., Vollset S. Coffee consumption and plasma total homocysteine: The Hordaland Homocysteine Study. Am J Clin Nutr. 65:1997;136-143.
46. Brattstrom L., Lindgren A., Israelsson B., Malinow M.R., Norrving B., Upson B., Hamfelt A. Hyperhomocysteinaemia in stroke: prevalence, cause, and relationships to type of stroke and stroke risk factors. Eur J Clin Invest. 22:1992;214-221.
47. Araki A., Sako Y., Fukushima Y., Matsumoto M., Asada T., Kita T. Plasma sulfhydryl-containing amino acids in patients with cerebral infarction and in hypertensive subjects. Atherosclerosis. 79:1989;139-146.
48. Fermo I., Vigano D., Paroni R., Mazzola G., Calori G., D'Angelo A. Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease. Ann Intern Med. 123:1995;747-753.